The use of weight-loss medications like semaglutide is becoming more and more popular. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to help with type 2 diabetes management and weight loss.
One area of less research is how semaglutide impacts bone health. Recent study results shared at the Endocrine Society meeting ENDO 2026 indicate that semaglutide was linked to higher weight loss and a 15% decrease in broken bones when it was compared to other weight loss medications.
These findings — which are yet to appear in a peer-reviewed journal — suggest that semaglutide may be beneficial for bone health. This current study involved people with type two diabetes who received weight-loss medication.
The study authors explain that in people with type 2 diabetes, weight loss interventions can increase the risk of bone breakage because people experience accelerated bone loss. They also note that semaglutide might benefit bone health and thus set out to compare it to other weight-loss medications.
Researchers utilized the Atropos Health Eos electronic health record dataset.
Medical News Today published a clinical update in Research Highlights on 15 Jun 2026.
The item focuses on GLP-1s may aid bone health as well as weight loss in type 2 diabetes.
Review the original article for the full source wording and details.